Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients

Executive Summary

TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.

Advertisement

Related Content

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019
IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year
Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate
Adaptimmune Hits High With TCR Platform Success With GSK Licensed Product
Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic
Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval
VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100603

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel